Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Elutia Inc ELUT.OQ reported a quarterly adjusted loss of 17 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -23 cents. The lone analyst forecast for the quarter was for a loss of 15 cents per share.
Revenue fell 61.2% to $2.43 million from a year ago; analysts expected $2.90 million.
Elutia Inc's reported EPS for the quarter was a loss of 17 cents.
The company reported a quarterly loss of $7.65 million.
Elutia Inc shares had fallen by 16.5% this quarter and gained 18.1% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Elutia Inc is $5.00, about 83.6% above its last closing price of $0.82
This summary was machine generated from LSEG data August 13 at 09:49 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.15 | -0.17 | Missed |
Mar. 31 2026 | -0.15 | -0.17 | Missed |
Dec. 31 2025 | -0.14 | 1.48 | Beat |
Sep. 30 2025 | -0.15 | -0.09 | Beat |
Recent news on Elutia
See all newsBrief: Elutia Receives $8 Million Payment From Boston Scientific Company Now Fully Funded Into 2029
Elutia Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Elutia Secures $15 Million Loan Financing From Avenue Capital Group
Elutia's Q2 revenue falls on SimpliDerm production disruption
Elutia Inc expected to post a loss of 15 cents a share - Earnings Preview